Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Quick Facts
What This Study Found
Octreotide LAR prolonged TTP vs placebo (14.3 vs 6.0 months; HR 0.34; P=0.000072) in 85 patients with metastatic midgut NETs.
Key Numbers
85 patients; TTP 14.3 vs 6.0 months; HR 0.34; P=0.000072
How They Did This
Phase 3, double-blind, placebo-controlled trial in metastatic midgut NETs.
Why This Research Matters
PROMID was the first RCT establishing antiproliferative effects of a somatostatin analog in NETs.
What This Study Doesn't Tell Us
Midgut only. Small sample. Included functional tumors.
Trust & Context
- Original Title:
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
- Published In:
- Journal of clinical oncology, 27(28), 4656-63 (2009)
- Authors:
- Rinke, Anja, Arnold, Rudolf
- Database ID:
- RPEP-01539
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01539APA
Rinke, Anja; Mueller, Hans-Helge; Schade-Brittinger, Carmen; Klose, Klaus-Jochen; Barth, Peter; Wied, Matthias; Mayer, Christoph; Aminossadati, Behrus; Pape, Ulrich-Frank; Blaeker, Michael; Wiedenmann, Bertram; Gress, Thomas M; Arnold, Rudolf; PROMID Study Group. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.. Journal of clinical oncology, 27(28), 4656-63. https://doi.org/10.1200/JCO.2008.18.0190
MLA
Rinke, Anja, et al. "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.." Journal of clinical oncology, 2009. https://doi.org/10.1200/JCO.2008.18.0190
RethinkPeptides
RethinkPeptides Research Database. "Placebo-controlled, double-blind, prospective, randomized st..." RPEP-01539. Retrieved from https://rethinkpeptides.com/research/rinke-2009-placebocontrolled-doubleblind-prospective
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.